30th week of 2013 patent applcation highlights part 35 |
Patent application number | Title | Published |
20130189238 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 2013-07-25 |
20130189239 | Conjugated Factor VIII Molecules - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 2013-07-25 |
20130189240 | COMPOSITION CONTAINING PIAS3 AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER OR IMMUNE DISEASE - The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells. | 2013-07-25 |
20130189241 | REGULATED DELIVERY SYSTEMS FOR INNER EAR DRUG APPLICATION AND USES THEREOF - The invention relates to a controlled release delivery compositions and methods of using them for pathologies associated with Otorhinolaryngology and Head and Neck. Specifically, the invention relates to regulating drug delivery by the use of chitosan based matrices together with chitosanases. | 2013-07-25 |
20130189242 | Hyaluronidase and Method of use Thereof - The present invention provides a tnaluronidase. The hyaiuronidase can be produced by the strain | 2013-07-25 |
20130189243 | BIOMARKERS FOR ACUTE ISCHEMIC STROKE - The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients. | 2013-07-25 |
20130189244 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 2013-07-25 |
20130189245 | METHOD FOR PRODUCING TOXOIDS USING ALPHA-DICARBONYL COMPOUNDS - The present invention relates to the use of toxoids prepared using a-dicarbonyl toxoiding reagents such as glyoxal, butanedione and phenylglyoxal. The toxoids may be prepared with low concentrations of toxoiding reagent and in short periods of time, often in as few as 24 hours, making the toxoiding reagents particularly advantageous when compared with traditional formaldehyde toxoiding. Toxoids prepared using dicarbonyl reagents such as phenylglyoxal are described and claimed as are pharmaceutical and vaccine compositions comprising the toxoids, methods of treatment using such compositions and antibodies generated by immunisation with the toxoid and methods of treatment using the antibodies so prepared or fragments of such antibodies. | 2013-07-25 |
20130189246 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES - Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina. | 2013-07-25 |
20130189247 | Multimeric Proteins Comprising Immunoglobulin Constant Domains - The present invention relate to small binding proteins comprising two or more protein domains derived from a CH2 domain or CH2-like domain of an immunoglobulin in which the CH2 domains have been altered to recognize one or more target proteins and, in some embodiments, retain, or have modified, certain secondary effector functions. | 2013-07-25 |
20130189248 | EGFR INHIBITOR AND ANTIVIRAL AGENT FOR SIMULTANEOUS, SEPARATE OR SEQUENTIAL USE IN THE TREATMENT AND/OR PREVENTION AND/OR PALLIATION OF CANCER - The application relates to a combination of biologically active compounds comprising at least one antiviral agent and at least one EGFR antagonist, for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of malignant or pre-malignant neoplasms, preferably of solid malignant or pre-malignant neoplasms. | 2013-07-25 |
20130189249 | METHODS AND COMPOSITIONS RELATED TO IMMUNIZING AGAINST STAPHYLOCOCCAL LUNG DISEASES AND CONDITIONS - Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing Hla to provide immunoprotection against | 2013-07-25 |
20130189250 | Human Tissue Factor Antibody and Uses Thereof - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs. | 2013-07-25 |
20130189251 | HUMANIZED ANTIBODIES TARGETING THE EC1 DOMAIN OF CADHERIN-11 AND RELATED COMPOSITIONS AND METHODS - The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer. | 2013-07-25 |
20130189252 | ANTIBODIES TO RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to antibodies, such as monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, for the treatment and diagnosis of pain and other neuroinflammatory conditions associated with the Receptor for Advanced Glycation End Products (RAGE). | 2013-07-25 |
20130189253 | MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides. | 2013-07-25 |
20130189254 | Inhibition of AXL/GAS6 Signaling in the Treatment of Disease - Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6. | 2013-07-25 |
20130189255 | FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS - The present invention relates to drug fusions of insulinotropic agents and incretin drugs that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. | 2013-07-25 |
20130189256 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF - Antiproliferative compounds having a structure represented by formula (II), where n, R | 2013-07-25 |
20130189257 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells. | 2013-07-25 |
20130189258 | THERAPEUTIC METHODS USING ANTI-CD200 ANTIBODIES - The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent. | 2013-07-25 |
20130189259 | ANTI-GLYCOPROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS - The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly | 2013-07-25 |
20130189260 | USE OF ANTIBODIES AGAINST ICAM-1 IN THE TREATMENT OF PATIENTS WITH RELAPSED CANCER - There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed. | 2013-07-25 |
20130189261 | TCR Complex Immunotherapeutics - Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided. | 2013-07-25 |
20130189262 | IL-27 Antagonists for Treating Inflammatory Diseases - Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA. | 2013-07-25 |
20130189263 | ANTIGEN-BINDING MOLECULE AND USES THEREOF - In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order V | 2013-07-25 |
20130189264 | A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV INFECTION - This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker. | 2013-07-25 |
20130189265 | MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY - Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. | 2013-07-25 |
20130189266 | MZB1, A NOVEL B CELL FACTOR, AND USES THEREOF - The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FO B cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes. | 2013-07-25 |
20130189267 | MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TIX) - The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs. | 2013-07-25 |
20130189268 | COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES - This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use. | 2013-07-25 |
20130189269 | ACTRIIB BINDING AGENTS AND USES THEREOF - The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same. | 2013-07-25 |
20130189270 | METHOD FOR THE PRODUCTION OF ANTIBODIES - The current invention is related to a method for the production of a human monoclonal antibody from a immundeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell. | 2013-07-25 |
20130189271 | MONOCLONAL ANTIBODIES AGAINST HER2 - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 2013-07-25 |
20130189272 | Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen - This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments. | 2013-07-25 |
20130189273 | EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE - The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis. | 2013-07-25 |
20130189274 | PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS - Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor. | 2013-07-25 |
20130189275 | COMPOSITIONS AND METHODS FOR INHIBITION OF OR TREATMENT OF DENGUE VIRUS INFECTION - The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. | 2013-07-25 |
20130189276 | METHOD INHIBITING CELL PROLIFERATION INDUCED BY ALTERNATIVELY SPLICED TISSUE FACTOR - Embodiments of the invention are directed to a method of inhibiting proliferation of a cell induced by asTF that includes exposing the proliferating cell to an inhibitor of asTF at a concentration sufficient to attenuate asTF induced proliferation. In an embodiment, the proliferating cell is a cancer cell such as a breast cancer cell. The inhibitor of asTF may be an anti-asTF antibody, such as a monoclonal antibody or an antibody fragment, a small molecule, a peptide, nucleic acid, and combinations thereof. | 2013-07-25 |
20130189277 | Stabilized Formulations Containing Anti-PCSK9 Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2013-07-25 |
20130189278 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2013-07-25 |
20130189279 | Binding Molecules Against Chikungunya Virus and Uses Thereof - The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules. | 2013-07-25 |
20130189280 | PROTEIN DOMAINS AND USES THEREFOR - The present disclosure relates generally to a structure-modeling approach to identify therapeutic and diagnostic targets on proteins. Means are provided to generate agents which bind and optionally antagonize a particular domain within a protein referred to as a Cleaved_Adhesin Family Domain. In an embodiment, the disclosure is directed to the control of | 2013-07-25 |
20130189281 | ANTIBODIES THAT BIND PAR-2 - The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions. | 2013-07-25 |
20130189282 | METHODS FOR ISOLATING AND USING A SUBSET OF CD8 T-CELLS THAT ARE RESISTANT TO CYCLOSPORIN - Utilizing a novel T cell culture system based on allogeneic epithelial antigen presenting cells (semi-professional APC), a cyclosporin-resistant CD8 T cell clone with minimal cytolytic capability was isolated. Derivation of the novel alloantigen-specific CD8 T cell clones involved previous priming with an allogeneic skin graft, implying expansion of this T cell subset during transplant rejection. Characterization and comparison of the cyclosporin and rapamycin-resistant CD 8 T cell clone with typical cyclosporin-sensitive CD 8 T cells suggests that it is a member of a CD8 T cell subset with a unique cell surface phenotype and novel TCR activation pathways, and that these unique CD8 T cell clones reflect the immunobiology of chronic rejection within the non-hematopoetic microenvironments of solid organs and vascular walls. These cells express the aryl-hydrocarbon receptor. T-cells of this type are referred to herein as CD8bm12-1 T-cells. | 2013-07-25 |
20130189283 | CARRIER IMMUNOGLOBULINS AND USES THEREOF - Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 2013-07-25 |
20130189284 | ANTIBODIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND DIABETES-ASSOCIATED AUTOANTIGENIC PEPTIDES - Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes. | 2013-07-25 |
20130189285 | ANTIBODIES AGAINST RAMP3 - Isolated antibodies capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor wherein the antibodies are of IgG, IgA or IgM isotype are provided, together with nucleic acid molecules encoding such antibodies, vectors comprising such nucleic acid molecules, host cells comprising such vectors, and methods of making the disclosed antibodies using such host cells. Also provided are compositions including the disclosed antibodies and methods of treating disorders, such as tumors, inflammatory disorders, cardiovascular disorders and osteoporosis, by administering such compositions. | 2013-07-25 |
20130189286 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 2013-07-25 |
20130189287 | ENZYMATIC CONJUGATION OF POLYPEPTIDES - The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions | 2013-07-25 |
20130189288 | ADJUVANT COMPOSITIONS AND METHODS OF USE - This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. | 2013-07-25 |
20130189289 | VACCINE FOR TREATMENT OF TAUTOPATHY - This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly. | 2013-07-25 |
20130189290 | VACCINE FOR THE PREVENTION OF BREAST CANCER RELAPSE - The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods. | 2013-07-25 |
20130189291 | Peptide Vaccines For Cancers Expressing Tumor-Associated Antigens - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines. | 2013-07-25 |
20130189292 | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions - Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual and related compounds and compositions. | 2013-07-25 |
20130189293 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 2013-07-25 |
20130189294 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2013-07-25 |
20130189295 | COMBINATIONS OF MENINGOCOCCAL FACTOR H BINDING PROTEINS - The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. | 2013-07-25 |
20130189296 | COMPOSITION FOR USE IN INHIBITING OR KILLING Phrphyromonas gingivalis AND USE IN APPLICATIONS FOR ALLEVIATING OR TREATING PERIDONTAL DISEASE AND RELATED DISEASES - A composition for use in inhibiting or killing | 2013-07-25 |
20130189297 | Dietary Supplement For Vascular Health - The present invention relates to an herbal dietary supplement to promote vascular health. The dietary supplement comprises L-Arginine, L-Citrulline, Ginkgo Biloba, Horse chestnut, Red Yeast Rice and Cayanne Pepper. | 2013-07-25 |
20130189298 | NOVEL YEAST STRAIN AND THE APPLICATION THEREOF - The present invention provides an isolated | 2013-07-25 |
20130189299 | Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same - The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a | 2013-07-25 |
20130189300 | CARRIER MOLECULE - The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are | 2013-07-25 |
20130189301 | Ablative immunotherapy - The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Th1 cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen. | 2013-07-25 |
20130189302 | IMMUNOTHERAPEUTIC METHOD USING ARTIFICIAL ADJUVANT VECTOR CELLS THAT CO-EXPRESS CD1D AND TARGET ANTIGEN - Provided is immunotherapy of cancer or infection utilizing activation of dendritic cell (DC) by innate immunity, namely, a method of preparing an artificial adjuvant vector cell co-expressing a target antigen and CD1d and having an ability to activate immunity against the target antigen, comprising treating the target antigen and CD1d co-expressing cell with a CD1d ligand in a culture medium. | 2013-07-25 |
20130189303 | RECOMBINANT SWINE INFLUENZA VIRUS AND USES THEREOF - Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection. | 2013-07-25 |
20130189304 | PRESERVATION OF BIOACTIVE MATERIALS BY FREEZE DRIED FOAM - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 2013-07-25 |
20130189305 | METHODS OF PRODUCING INFLENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 2013-07-25 |
20130189306 | Flavivirus Vaccines - The invention provides flavivirus vaccines and methods of making and using these vaccines. | 2013-07-25 |
20130189307 | METHOD OF TREATING DEPRESSION - Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject. | 2013-07-25 |
20130189308 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against | 2013-07-25 |
20130189309 | CELLS EXPRESSING MODIFIED T CELL RECEPTOR - This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a trans-membrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs. | 2013-07-25 |
20130189310 | AUTOLOGOUS CANCER CELL VACCINE - An autologous cancer cell vaccine comprises cancer cells that express both MHCI and MHCII on their cell surface. The MHCI presents a cancer antigen and the MHCII presents a non-self antigen. | 2013-07-25 |
20130189311 | ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber. | 2013-07-25 |
20130189312 | NOVEL COATING SYSTEM - The present patent application relates to a novel coating system, coated compositions with such a coating system, as well as to the use of such compositions in the production food, feed, dietary supplements and/or pharmaceutical products, as well as to food, feed, dietary supplements and/or pharmaceutical products comprising such compositions. | 2013-07-25 |
20130189313 | ADHESIVE COMPLEX COACERVATES AND METHOD OF MAKING AND USING THEREOF - Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. They have numerous biological applications as bioadhesives and drug delivery devices and are particularly useful in underwater applications and situations where water is present such as, for example, physiological conditions. | 2013-07-25 |
20130189314 | ENTERIC-COATED HT-2157 COMPOSITIONS AND METHODS OF THEIR USE - Drug compositions comprising the compound HT-2157 and their therapeutic uses, including the treatment of CNS disorders and cognitive impairments and the modulation of cognitive function, are disclosed. More particularly, the present invention relates to enteric-coated formulations comprising HT-2157 that reduce the appearance of clinically relevant methemoglobinemia relative to administration of non-enteric-coated formulations comprising HT-2157. | 2013-07-25 |
20130189315 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer. | 2013-07-25 |
20130189316 | NANOEMULSION COMPOSITION CONTAINING VITAMIN K - In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP. | 2013-07-25 |
20130189317 | NOVEL DOSAGE AND FORMULATION - The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide. | 2013-07-25 |
20130189318 | Solid dispersions comprising tacrolimus - A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability. | 2013-07-25 |
20130189319 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors. | 2013-07-25 |
20130189320 | METHOD OF PREPARING A CONTROLLED RELEASE PARTICLE OF SOY ISOFLAVONE WITH BIODEGRADABLE POLYMER USING A SUPERCRITICAL FLUID EXTRACTION OF EMULSION (SFEE) PROCESS - A method of preparing a controlled release particle of soy isoflavone (e.g. genistein) with a bio-degradable polymer is disclosed herein. The method employs a supercritical fluid extraction of emulsion (SFEE) process for encapsulating soy isoflavone into a bio-degradable polymer matrix (e.g. PLGA) to form a particle which is suitable for oral administration or inhalable administration in a controlled release manner and with an improved bioavailability of the soy isoflavone. A system for preparing the controlled release particle of the soy isoflavone with the bio-degradable polymer using the SFEE process is also disclosed herein. | 2013-07-25 |
20130189321 | Parental Composition Comprising Microsperes with a Diameter between 10 and 20 Microns - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. | 2013-07-25 |
20130189322 | Chromatographic Media for Storage and Delivery of Therapeutic Biologics and Small Molecules - Described are composite materials and methods of making and using them for the storage and delivery of unstable drugs or biologics. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through the support member; a macroporous cross-linked gel, comprising a plurality of macropores; a therapeutic agent; and a stabilizing agent. | 2013-07-25 |
20130189323 | ANTIBACTERIAL AND OSTEOINDUCTIVE IMPLANT COATING, METHOD OF PRODUCING SUCH COATING, AND IMPLANT COATED WITH SAME - A calcium phosphate/copper coating for an implant is provided which includes highly porous calcium phosphate and predominantly discontinuously distributed copper. The highly porous calcium phosphate first forms a highly porous calcium phosphate layer in which the copper has been incorporated so as to be discontinuously distributed, to form the calcium phosphate/copper coating. Further provided are a method of producing such a calcium phosphate/copper coating and an implant coated therewith. | 2013-07-25 |
20130189324 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION - Dry powder formulations comprising a corticosteroid and a beta | 2013-07-25 |
20130189325 | METHODS OF APPLYING COATING MATERIALS FOR SOLID MEDICINES - A method improves stability of drugs in a solid pharmaceutical formulation against oxygen and water vapor by coating the solid pharmaceutical formulation with a coating material including a high hydrogen-bonding resin and a swelling clay. | 2013-07-25 |
20130189326 | METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY - The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nanosilicate platelets. | 2013-07-25 |
20130189327 | LIVER ORGANOID, USES THEREOF AND CULTURE METHOD FOR OBTAINING THEM - The invention relates to a liver organoid, uses thereof and method for obtaining them. | 2013-07-25 |
20130189328 | PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L | 2013-07-25 |
20130189329 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES - Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups. | 2013-07-25 |
20130189330 | Enteral Nutrient - Provided is an enteral nutrient which, although containing a soy protein as a protein source, does not cause a rapid increase in viscosity and inhomogeneity due to aggregation or thermal denaturation by heating for sterilization or formulation step and is thus stable, and shows a good taste without giving any sense of bitterness and coarseness on the throat inherent to soybean. The enteral nutrient is an enteral nutrient of acidic type which comprises a protein, a fat, a carbohydrate, a vitamin, a mineral and a food fiber and has a pH of 3.0 to 4.5, wherein a soy protein containing 20 to 40% of a peptide fraction having a molecular weight of less than 6000 is formulated in an amount of 5 to 65% of the total protein. | 2013-07-25 |
20130189331 | SURFACE-TREATED POWDER AND A METHOD OF PRODUCING IT, AND COSMETICS COMPRISING THE SURFACE-TREATED POWDER - The objects of the present invention are to provide a surface-treated powder that is excellent in water repellency and oil repellency and provides smooth texture and good adhesion when applied to skin, to produce the surface-treated powder simply and inexpensively, and to provide cosmetics comprising the surface-treated powder. Specifically, according to the present invention, a surface-treated powder wherein the surface of a material powder is treated with perfluoropolyetherphosphate represented by general formula (1) and an anionic polymer having a perfluoropolyether chain, which is represented by general formula (2), or perfluoropolyetherphosphate represented by general formula (1) and a cationic polymer having a perfluoropolyether chain, which is represented by general formula (3), and cosmetics comprising the surface-treated powder are provided. | 2013-07-25 |
20130189332 | METHODS FOR SMOOTHING WRINKLES AND SKIN TEXTURE IMPERFECTIONS - A method for smoothing skin comprising applying a composition that has from about 0.5 to about 4% sodium silicate as measured by silica content (SiO | 2013-07-25 |
20130189333 | ORAL PRODUCT - An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva. | 2013-07-25 |
20130189334 | ENHANCING PROPERTIES BY THE USE OF NANOPARTICLES - Composite materials comprising nanoparticles functionalized with metals are disclosed. The composite materials may be used in a variety of applications, including in coating compositions, cosmetic and pharmaceutical compositions, absorbent articles, and the like. | 2013-07-25 |
20130189335 | Oil-in-Water Emulsified Composition - The present invention provides an oil-in-water emulsified composition comprising the following ingredients (A)-(G) characterized by miniaturization of the emulsified particles by means of high pressure emulsification:
| 2013-07-25 |
20130189336 | Cosmetic Compositions Including Ivy Derived Nanoparticles - Ivy derived nanoparticles and methods for their preparation and use are described herein. Further described herein are cosmetic compositions containing the ivy derived nanoparticles and methods for their use as sunscreens. | 2013-07-25 |
20130189337 | DENTINAL TUBULE SEALANT AND METHOD FOR PRODUCING THE SAME - A dentinal tubule sealant comprises poorly-soluble calcium phosphate particles (A), a phosphorus-free calcium compound (B), and water (C), wherein the particles (A) are at least one member selected from the group consisting of dicalcium phosphate anhydrous [CaHPO | 2013-07-25 |